Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
Faggiano A, Carratù AC, Guadagno E, Tafuto S, Tatangelo F, Riccardi F, Mocerino C, Palmieri G, Damiano V, Siciliano R, Leo S, Mauro A, Tozzi LF, Battista C, De Rosa G, Colao A. Faggiano A, et al. Among authors: tozzi lf. Oncotarget. 2016 Feb 2;7(5):5538-47. doi: 10.18632/oncotarget.6686. Oncotarget. 2016. PMID: 26701729 Free PMC article.
Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group.
Faggiano A, Di Maio S, Mocerino C, Ottaviano M, De Divitiis C, Guarnotta V, Dolce P, Modica R, Puliafito I, Tozzi L, Di Sarno A, Leo S, Riccardi F, Palmieri G, Tafuto S, Bianco A, Badalamenti G, Colao A; ELIOS. Faggiano A, et al. Endocrine. 2019 Nov;66(2):417-424. doi: 10.1007/s12020-019-01894-0. Epub 2019 Mar 14. Endocrine. 2019. PMID: 30875056
Letter: the response to somatostatin analogues in neuroendocrine tumours is influenced by the Ki67 score.
Faggiano A, Carratù AC, Guadagno E, Tafuto S, Tatangelo F, Riccardi F, Mocerino C, Palmieri G, Damiano V, Siciliano R, Leo S, Mauro A, Tozzi LF, Battista C, De Rosa G, Colao A. Faggiano A, et al. Among authors: tozzi lf. Aliment Pharmacol Ther. 2015 Oct;42(8):1033-4. doi: 10.1111/apt.13381. Aliment Pharmacol Ther. 2015. PMID: 26374262 Free article. No abstract available.
Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.
Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D'Avolio A, Priola AM, Birocco N, Amoroso V, Biasco G, Papotti M, Dogliotti L. Berruti A, et al. BMC Cancer. 2014 Mar 14;14:184. doi: 10.1186/1471-2407-14-184. BMC Cancer. 2014. PMID: 24628963 Free PMC article. Clinical Trial.